Blackwell Kimberly 4
4 · Zentalis Pharmaceuticals, Inc. · Filed May 20, 2022
Insider Transaction Report
Form 4
Blackwell Kimberly
Director
Transactions
- Award
Stock Option (Right to Buy)
2022-05-16+1,708,809→ 1,708,809 totalExercise: $24.41Exp: 2032-05-15→ Common Stock (1,708,809 underlying) - Award
Stock Option (Right to Buy)
2022-05-16+427,202→ 427,202 totalExercise: $24.41Exp: 2032-05-15→ Common Stock (427,202 underlying)
Footnotes (2)
- [F1]The option vests and becomes exercisable as to 25% of the shares on May 16, 2023 and vests in equal monthly installments thereafter until May 16, 2026.
- [F2]The option vests and becomes exercisable as to 100% of the shares on the earlier of (a) FDA approval of a Zentalis product or (b) a Change in Control (as defined in the Issuer's 2020 Incentive Award Plan).